FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the therapeutic use of the GDF trap fusion protein, and can be used in medicine for treating anaemia and/or increased erythrocyte count. Disclosed is the use of an ActRII fusion protein containing ActRIIB fragment 25-131 with a L79D substitution linked through a linker domain to an immunoglobulin Fc domain.
EFFECT: invention provides the use of the GDF trap fusion protein in the treatment of anaemia and to increase the erythrocyte level, the ActRII composition of which exhibits a loss of binding to activin A and activin B, but retains the ability to bind to GDF11 as compared to the fused ActRII protein which does not contain the L79D mutation.
18 cl, 22 dwg, 10 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GBO-ACTRIIB RECOMBINANT PROTEIN FOR INCREASING MUSCLE MASS IN FARM ANIMALS AND POULTRY | 2022 |
|
RU2792817C1 |
| NUCLEOTIDE SEQUENCE ENCODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN Dll4 AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2021 |
|
RU2787060C1 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
| FUSION POLYPEPTIDE INCLUDING Fc REGION OF IMMUNOGLOBULIN AND GDF15 | 2020 |
|
RU2797520C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| MULTIVALENT PD-L1-BINDING COMPOUNDS FOR TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2816646C2 |
| CARRIER CONTAINING A DRUG INTO A CELL FOR FORMING AN IMMUNE COMPLEX | 2012 |
|
RU2739792C1 |
| METHOD OF PRODUCING A POLYPEPTIDE HETEROMULTITERS | 2014 |
|
RU2730594C2 |
| TGF-BETA RECEPTOR ECTODOMAIN FUNCTIONS AND THEIR USE | 2018 |
|
RU2797464C2 |
